Health
STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
Publication: STAT
Author: Ed Silverman
Source published: 13/11/2026, 14:33:16 UTC
Briefing created: 14/11/2026, 10:46:52 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 14/11/2026, 10:07:24 UTC.
Briefings
The provided evidence reports on two distinct pharmaceutical supply issues: the U.S. Drug Enforcement Administration (DEA) approved Orzeyful, a narcolepsy pill, as a Schedule IV controlled substance after removing regulatory hurdles, and Pfizer discontinuing Premarin vaginal cream in Canada due to a shortage. The text also notes that the U.S. Food and Drug Administration removed safety warnings for these drugs a year ago. The evidence does not specify the exact date of the Orzeyful approval beyond the general timeframe of the article's publication in November 2026, nor does it provide specific sales figures or patient counts for the narcolepsy disorder other than the general U.S. population estimate of 120,000.
Key points
- The U.S. Drug Enforcement Administration (DEA) approved Orzeyful, a narcolepsy pill, as a Schedule IV controlled substance after removing the final regulatory hurdle for its rollout.
- Pfizer discontinued the sale of Premarin vaginal cream in Canada following an internal review due to a shortage of hormone replacement therapy products.
Context
The article discusses recent pharmaceutical supply issues in the United States and Canada, specifically focusing on the approval of Orzeyful for narcolepsy and the discontinuation of Premarin in Canada. These events highlight ongoing challenges in drug availability and safety warnings removal.
Limitations
The evidence does not specify the exact date of the Orzeyful approval beyond the general timeframe of the article's publication in November 2026, nor does it provide specific sales figures or patient counts for the narcolepsy disorder other than the general U.S. population estimate of 120,000. The text does not mention the specific city or region where the Premarin shortage occurred, other than Canada.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 14/11/2026, 10:46:52 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeie6i6ksymiruuvxyhnc32oqqxy7wpuit42zh4y2ecxq3uxipq6wnu